Newsletter
Impulse – Meeting Healthcare Pioneers

Impulse – Meeting Healthcare Pioneers

The podcast that democratizes medical technology and meets the people who are transforming this field.

#28 – Modeling embryos to understand early life – Jacob Hanna – Weizmann Institute of Science

Because of ethical and medical challenges, early human embryo development remains “a black box” to us, as Prof. Jacob Hanna himself puts it. Despite all the progress made in medicine over the past decades, there is still a whole lot to learn about the causes of miscarriages, infertility, or early developmental defects. In 2023, Jacob’s group from the Weizmann Institute of Science published a pivotal paper in Nature that redefines how we study developmental biology, with the potential to accelerate our understanding of early human life. Their achievement? The creation of the first synthetic embryo model closely resembling a day-14 fetus, obtained “ex utero” without gametes and outside a womb. A human embryo model derived from “naive” stem cells in the lab, which can be obtained from “adult” cells that make up our body (like skin cells for instance). A technology that could generate embryo models of ourselves based on a simple cell sample. This work had an unprecedented impact on the scientific community and the general public, being named by TIME Magazine as one of the 100 best inventions of 2023. A breakthrough that raises important ethical, technical, and legal questions. I had the honor of meeting Jacob for this episode of Impulse, with whom we discuss the functioning of this fascinating technology, its potential medical applications in the future, and the key societal questions it raises. A conversation where we dive into the magic of human development, with a stellar scientist and advocate for responsible scientific research! Timeline: (00:02:58) - Jacob’s journey from his medical practice to studying developmental biology (00:06:09) - Why we know so little about early human development (00:08:45) - Jacob’s lab breakthrough in modeling human embryos (00:16:20) - Reprogramming cells to their “naïve” state (00:18:09) - Dealing with your research being put under the spotlight (00:20:02) - The “recipe” to create human embryo models without gametes and outside a womb (00:27:22) - Ethical considerations and how far we can go with this technology (00:35:15) - Potential medical applications for the future (00:38:05) - Jacob’s role as an adviser to the startup Renewal Bio What we also talked about with Jacob: Prof. Shinya Yamanaka (2012 Nobel Prize in Physiology or Medicine with Prof. John Gurdon) Induced pluripotent stem cells (iPSCs) Embryonic stem cells International Society for Stem Cell Research (ISSCR) Taledomide We cited with Jacob some of the past episodes of the series:: #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden As mentioned by Jacob during the episode, we recommend the book “The Master Builder” by Prof. Alfonso Martinez Arias, challenging the traditional thinking where cells (and not DNA) may hold the key to understanding life’s past and present. Feel free to follow the Weizmann Institute of Science on LinkedIn. You can contact Jacob via email and follow his activities on LinkedIn, X, and Facebook! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 There’s now a bi-monthly newsletter around the podcast where you will be informed of the latest episodes and kept posted on the latest medical tech progress, subscribe here! Lastly, don’t forget to follow our activities on LinkedIn and our website!
May 7, 2024

[EXTRACT] – Jacob Hanna on the ethical implications of human embryo models

To discover the whole episode type "#28 - Modeling embryos to understand early life - Jacob Hanna - Weizmann Institute of Science" on your streaming platform.
May 7, 2024

#27 – Reinventing neuroelectronic therapies – Carolina Aguilar – Inbrain Neuroelectronics

We are at a turning point for brain-computer interfaces (BCIs) and neurotechnology. We have all witnessed phenomenal progress in this field recently via images shared by Neuralink, showing paralyzed patients who can communicate with a computer through their own thoughts. Other fascinating applications, such as those being worked on by Gregoire Courtine and Jocelyne Bloch, enable paraplegics to regain an unprecedented degree of walking mobility. These advancements are mind-blowing and illustrate the potential of these technologies to address conditions that have a major impact on quality of life. What if we were to enhance the physical properties of these implants while making them more accessible in terms of costs to health systems? Where could this paradigm shift take us, and what prospects could it open up for treating complex neurological disorders? This is what we explore in this episode with Carolina Aguilar, CEO of Inbrain Neuroelectronics, a company developing a cutting-edge neural platform based on graphene, promising to change the way we decode, modulate, and stimulate neuronal activity. We talk with Carolina about: How Inbrain Neuroelectronics' technology enhances the resolution of BCIs and their therapeutic potential The stakes around BCIs and their promise in treating serious neurological disorders The importance of focusing their development around therapeutic indications vs. aiming for human augmentation The commercialization of these solutions through a value-based care approach and key success factors Empowering women in science and business An outlook on the future of brain therapies that bridges the gap between reality and science fiction! Timeline: (00:03:22) - Explaining Inbrain Neuroelectronics’ neural platform (00:07:32) - The medical need for BCIs and the first indications targeted by Inbrain Neuroelectronics (00:18:46) - Risks around BCIs and ethical considerations for the field to head in the right direction (00:26:17) - Toward value-based commercial models for BCIs (00:29:40) - Transitioning from Medtronic to an early-stage Medtech startup (00:33:29) - Empowering women in science and business What we also talked about with Carolina: Neuralink Elon Musk Sapiens Steering Brain Stimulation Medtronic ONWARD Medical Precision Neuroscience Paradromics Synchron Neurosoft Bioelectronics We cited with Carolina some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore As mentioned by Carolina during the episode, you can access Inbrain Neuroelectronics’ publications here and learn more about their ongoing research and therapy development efforts. You can listen to the Neurotech Pub podcast hosted by Matt Angle here. Feel free to follow Inbrain Neuroelectronics activities on LinkedIn. If you want to contact Carolina, you can reach out to her over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at [email protected]! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 There’s now a monthly newsletter around the podcast where you will be informed of the latest episodes and updated on the latest medical tech progress, subscribe here! Lastly, don’t forget to follow our activities on LinkedIn and our website!
April 7, 2024

[EXTRACT] – Carolina Aguilar on the future of neurotechnology

To discover the whole episode type "#27 - Reinventing neuroelectronic therapies - Carolina Aguilar - Inbrain Neuroelectronics" on your streaming platform.
April 7, 2024

#26 – Redefining allergy care – Kenneth Chahine – Nectar Life Sciences

Many of us struggle with allergies, usually something we’ve been dealing with our whole life, either continuously or episodically. Be it related to food, pollen, dust, pets, or many others, it’s quite a pain and it can take us away from many things we appreciate in life. And I deliberately include myself in this group. Somehow it was engraved in my brain as a condition one needs to cope with, without much opportunity for improvement. It turns out companies like Nectar Life Sciences are redefining the way we detect and treat allergies from the comfort of our homes. Based on the latest science in this field, and backed by his extensive experience in consumer healthcare, Kenneth Chahine and his team are transforming the experience of allergy care for patients, offering a convenient and personalized approach to it. In this revealing episode, we talk with Kenneth about: The inconvenience of past approaches to allergy detection and treatment How allergy immunotherapy works and can be delivered through a few drops delivered to the tongue How Nectar Life Sciences enables personalized allergy immunotherapy for patients The transformative power of preventing acute allergic shocks Lessons learned from a serial healthcare entrepreneur at the interface of genetics, biochemistry, and intellectual property A conversation with a tireless figure in healthcare entrepreneurship, shedding light on one of the largest chronic conditions globally and how it can be tackled in a modern way! Timeline: 02:28 - Kenneth’s background at the interface of genetics, biochemistry and intellectual property 04:14 - The global burden of allergies as a chronic condition 05:53 - Origins of allergies 07:49 - Immunotherapy or how to train your immune system to be desensitized to allergens 09:43 - Detecting which allergens you are sensitive to 11:17 - How Nectar Life Sciences approaches allergy treatment 22:11 - Kenneth’s mindset toward solving complex healthcare challenges in new ways 26:01 - Opportunities beyond allergy care 32:16 - Kenneth’s advice to fellow healthcare entrepreneurs What we also talked about with Kenneth: Avigen Ancestry Anaphylaxis Neurimmune University of Utah We cited with Kenneth some of the past episodes from the series: 15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic As mentioned by Kenneth during the episode, you can access Nectar Life Sciences’ Learning Hub here and learn more about Prof. Edwin H. Kim’s research there. Feel free to follow Nectar Life Sciences activities on Instagram, Facebook, and TikTok! If you want to contact Kenneth, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at [email protected]! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 There’s now a monthly newsletter around the podcast where you will be informed of the latest episodes and updated on the latest medical tech progress, subscribe here! Lastly, don’t forget to follow our activities on LinkedIn and our website!
February 4, 2024

[EXTRACT] – Kenneth Chahine on being dogmatic about improving allergy care

To discover the whole episode type "#26 - Redefining allergy care - Kenneth Chahine - Nectar Life Sciences" on your streaming platform.
February 4, 2024

#25 – Stopping a bleed in three seconds – Joe Landolina – Cresilon

We don’t need to look far in the daily news to understand the stakes and the importance of having efficient solutions to control and stop bleeding. In the times we live in, where the world is crippled by a series of humanitarian catastrophes (some of natural origin, some of human origin), technological wonders from the medical field make me truly hopeful about the future, and about what we can achieve as humans. One of them is the hemostatic gel - a gel that can stop bleeding - that Joe Landolina and his team at Cresilon created. And its astonishing performance is easy to grasp: any bleed can be stopped within three seconds. Compared to traditional methods that require several minutes, it can mean the difference between life and death. There’s so much that impresses in Joe’s journey since the foundation of Cresilon: the fact that he developed the gel formulation himself, that he founded the company at 17 years old in his first year at University, or that Cresilon now represents the largest biotech manufacturing site in New York, and so much more! Beyond these successes, this episode is an ode to biomimicry and the science of biomaterials. Joe reveals everything about the functioning of this revolutionary medical product, its ability to stop bleeding almost instantly, and what it changes in medicine for the treatment of superficial injuries, but especially for the most severe traumatic cases. A surprising encounter with a prodigious entrepreneur, building his path on resilience and adaptability, with the long-term vision to transform bleeding control in humans! Timeline: 02:23 - Joe’s background and founding Cresilon in his first year in college 06:15 - Cresilon’s mission and the technology at its core 08:42 - How the hemostatic gel from Cresilon compares to traditional bleeding control methods 10:40 - The explanation behind Cresilon’s hemostatic gel unique performance 16:06 - How the gel is applied and removed 21:44 - Marketing first the product for veterinary application before moving to human use 25:27 - Being the only biotech company with manufacturing capabilities in New York 34:15 - Setting up the company to become a large medtech player in the long term What we also talked about with Joe: New York University Columbia University Scar tissue formation Fibrin Extracellular matrix Hurricane Sandy American Veterinary Medical Association Roche Pfizer Cutiss We cited with Joe some of the past episodes from the series: 18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics Feel free to follow Cresilon’s activities on LinkedIn! You will find here the TED Talk that Joe held in 2015, and here the Medsider podcast episode between Joe and Scott Nelson that we mention in this episode of Impulse. If you want to contact Joe, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at [email protected]! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 There’s now a bi-monthly newsletter around the podcast where you will be informed of the latest episodes and updated on the latest medical tech progress, subscribe here! Lastly, don’t forget to follow our activities on LinkedIn and our website!
November 12, 2023

[EXTRACT] – Joe Landolina on the criticality of rapid bleeding control in medicine

To discover the whole episode type "#25 - Stopping a bleed in three seconds - Joe Landolina - Cresilon" on your streaming platform.
November 12, 2023
View All Episodes

Listen on your favorite player

New to Podcasts? It's easy to get started!

Impulse - Meeting Healthcare Pioneers

Impulse invites listeners to meet the people shaping the current medical advancements through in-depth conversations about their field of expertise and the journey that took them where they are now. The podcast aims to democratize ongoing advances in medical technology and to introduce listeners to some of its key actors.

Host

Mathieu Chaffard

Mathieu Chaffard

Mathieu is a French biomedical engineer, trained at the Swiss Federal Institute of Technology in Lausanne.

Passionate about medical technology applied to cardiac indications, he has occupied different technical roles in Europe, including Development Engineer for B. Braun in Berlin and Field Specialist for Abbott in Paris, before moving to project management in the digital health space for Roche Diagnostics in Zürich.

Wishing to share his passion for medical progress on a broad scale and driven by an ongoing desire to learn more about its aspects, he has decided to create his own show where he talks with entrepreneurs, researchers and physicians about their personal journey and the innovative technologies they are developing to transform patients' lives.

You may also like

Join our community and never miss
your favorite episodes

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners